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OBJECTIVES This study prospectively analyzed atrial tachyarrhythmia (AT) organization and antitachy-
cardia pacing (ATP) success in patients with an implanted device for AT therapy.
BACKGROUND In patients with atrial fibrillation (AF), the incidence of regular, slow ATs amendable by ATP
is unknown.
METHODS Forty patients with previously documented AT (70% with AF) received a new pacemaker
with atrial electrogram (AEG) storage and atrial ATP capabilities for standard pacing
indications. The AEGs acquired during the first month (study phase 1) were classified into
high (type I), intermediate (type II) and low (type III) degrees of organization. Atrial ATP
was then activated, and treated AT episodes were retrieved three and six months after
implantation (study phase 2).
RESULTS Of 824 AEGs retrieved before ATP activation (study phase 1), 351 (43%) were classified as
type I, 47% as type II and 10% as type III. Episodes of AT starting as type I (35%) and type
II or III (65%) maintained their type over 1 min in 73%. All patients with an exclusive history
of AF also showed type I AEGs. In 361 subsequently treated AT episodes (study phase 2),
ATP was successful in 62% of type I and 34% of type II episodes, but not in type III (p ,
0.0001).
CONCLUSIONS The majority of patients with a history of AF show not only disorganized but also highly
organized AT episodes, which can be successfully terminated by ATP. (J Am Coll Cardiol
2001;38:355–63) © 2001 by the American College of Cardiology
Different approaches to improve treatment of atrial tachy-
arrhythmias (ATs), such as new antiarrhythmic drugs,
catheter ablation techniques, atrial pacing for prevention of
AT onset, atrial overdrive pacing and internal atrial defi-
brillation, are currently under investigation. Antiarrhythmic
drug treatment of AT is limited by a relatively low success
rate of maintaining sinus rhythm and proarrhythmic side
effects (1). Atrial defibrillation, on the other hand, is highly
effective in restoring sinus rhythm, but the associated
discomfort and pain limit its widespread use (2). The
possibility of automatically pace-terminating ATs by an
implanted device is a promising new therapeutic avenue.
However, atrial antitachycardia pacing (ATP) will termi-
nate only regular AT, such as atrial flutter, but not atrial
fibrillation (AF) (3). Knowledge of AT organization is
derived from atrial electrograms (AEGs) in animal models
(4), recordings during human electrophysiologic studies
(5,6) and temporary atrial leads implanted during cardiac
surgery (7). It is not known how many spontaneous ATs
during daily life consist of regular, relatively slow episodes,
which may be amendable by painless termination by ATP.
Moreover, it is unclear whether the degree of AT organi-
zation is stable over a short period. Accordingly, it is
unknown whether automatic atrial ATP should be applied
early after onset of AT, before it disorganizes, or later to
allow for spontaneous conversion to more organized
rhythms or eventually to sinus rhythm. Thus, this prospec-
tively designed study evaluated the degree of AT organiza-
tion during the first minute after its onset, as well as the
success rate of automatic atrial ATP related to AT organi-
zation, using an implanted device with dedicated capabili-
ties for AT monitoring and treatment.
METHODS
Study group. Patients with a class I indication for perma-
nent pacemaker therapy, according to accepted guidelines
(8), and ATs documented by rest electrocardiography or
24-h Holter monitoring within three months before im-
plantation were eligible for the study. Records were kept for
antiarrhythmic drug treatment before and after pacemaker
implantation. All patients gave written, informed consent.
The study protocol was approved by the institutional ethical
committees.
Device specifications. In all patients, a DDDRP pace-
maker system (AT500 model 7253, Medtronic Inc., Min-
neapolis, Minnesota) was implanted. This system offers
DDDR pacing with automatic atrial ATP (adaptive ramp
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and burst-plus protocols) and storage capabilities for 35 AT
episodes. The ATs are automatically stored using a detec-
tion algorithm combining the rate with P:R pattern infor-
mation (PR Logic™, Medtronic). An automatic algorithm
adjusts the atrial sensitivity after each sensed or paced atrial
event to avoid ventricular far-field oversensing. Each epi-
sode report contains an AT summary and marker annota-
tions with atrial and ventricular beat-to-beat cycle length of
144 cycles. Simultaneously, a bipolar AEG recorded
through the implanted atrial lead is stored for up to 4 s at
the onset of the AT episode and for up to 4 s at confirma-
tion of AT persistence 1 min later.
Data acquisition. This prospective study comprised two
successive phases. During the first phase (first month after
implantation), AEGs of up to 35 AT episodes per patient
(AT cycle length ,360 ms) were stored by the devices; ATP
functions remained deactivated. One month after implan-
tation, the second phase started with activation of ATP
modalities for AT episodes lasting .1 min. During the
subsequent five-month period, only AT episodes treated by
ATP were acquired. Stored AT episodes were downloaded
on disk, subsequently printed out and analyzed. Antitachy-
cardia pacing was delivered for slow, regular AT episodes
(median cycle length 220 to 360 ms, difference between
second longest and second shortest AA interval #25% of
median AA interval). Antitachycardia pacing was pro-
grammed to eight sequences of adaptive ramp (91% of AA
interval, 10-ms decrement, 4 initial beats), six sequences of
burst-plus (91% of AA interval, 84% S1S2, 20-ms S2S3,
10-ms decrement, 8 initial beats) and four sequences of a
more aggressive burst-plus protocol (91% of AA interval,
75% S1S2, 20-ms S2S3, 10-ms decrement, 15 initial beats).
Analysis of episodes and definitions. Stored electrograms
were manually analyzed (by Dr. Israel) in the following way:
1) Confirmation of sustained AT; episodes consisting of
nonsustained AT, only oversensing artifacts or severe un-
dersensing precluding reliable evaluation of sensed poten-
tials and cycle lengths were excluded from analysis. 2)
Evaluation of AT type at onset and at confirmation of AT
persistence; AT classification on the basis of AEG mor-
phology, including cycle length information (modified from
[9]) (Table 1), was prospectively used to define three types
of AT (Fig. 1): type I—highly organized AT, defined as a
discrete deflection of constant morphology with an isoelec-
tric line between signals and a minimal cycle length
$200 ms; type II—intermediate type of organization, so
classified if morphology and cycle length did not meet the
definition of either type I or type III (e.g., an AT with
discrete monomorphic narrow signals and a minimal cycle
length ,200 ms or an AT with polymorphic deflections and
a clear isoelectric line); and type III—disorganized AT,
defined as polymorphic deflections without an isoelectric
line between signals and a minimal cycle length ,200 ms.
Each stored AEG (at AT onset and AT confirmation 1 min
later) was assigned to one type of AT. If there were clearly
two different types of AT on one AEG, two types of AT
were classified. 3) Evaluation of atrial ATP success; for each
Abbreviations and Acronyms
AEG 5 atrial electrogram
AF 5 atrial fibrillation
AT 5 atrial tachyarrhythmia
ATP 5 antitachycardia pacing
AV 5 atrioventricular
CI 5 confidence interval
GEE 5 Generalized Estimating Equation
Table 1. Classification of Atrial Tachyarrhythmias on the Basis of Atrial Electrograms
Wells (9) Barbaro (12) Jung (13) Konings (18) Kuck (19) Israel
Type I: discrete
complexes of variable
morphology separated
by an isoelectric
baseline free of
perturbations
Type I: like (9),
using CV, NP
and BW
Atrial flutter:
MACL
.170 ms, index
of irregularity
,7.5%
Type I: single, broad
wavefront of
activation at free wall
of right atrium
Type A: regular
activation
separated by a
clear isoelectric
line
Type I: monomorphic
discrete signals
separated by an
isoelectric line with
a minimal cycle
length $200 ms
Type II: discrete
complexes of variable
morphology, with
perturbations at
baseline
Type II: like (9),
using CV, NP
and BW
Atrial fibrillation:
MACL
#170 ms, index
of irregularity
.7.5%
Type II: one or two
nonuniformly
propagating
wavefronts of
activation at free wall
of right atrium
Type B: irregular
activation,
perturbations at
baseline and/or
fragmented
electrograms
Type II: meets neither
type I nor type III
definition
Type III: no discrete
complexes and no
isoelectric intervals
Type III: like (9),
using CV, NP
and BW
Type III: multiple
reentrant wavelets
simultaneously within
area of electrode
array
Type C:
alternations
between A
and C
Type III: polymorphic
or nondiscrete
signals, no
isoelectric baseline,
minimal cycle
length ,200 ms
Type IV: type III
alternating with type
I or II
BW 5 electrogram bandwidth; CV 5 coefficient of variation; MACL 5 mean atrial cycle length; NP 5 number of points at baseline.
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Figure 1. Classification of atrial tachyarrhythmia (AT) on the basis of analysis of stored bipolar electrograms. a) Type I: highly organized AT with discrete
deflections of constant morphology, an isoelectric line between signals and a minimal cycle length $200 ms. b) Type II: intermediate type of organization
not meeting the definition of type I or type III. c) Type III: disorganized AT with polymorphic deflections, no isoelectric line between signals and a minimal
cycle length ,200 ms. AS 5 atrial sense; FD 5 fibrillation detection interval; FS 5 fibrillation sense; TF 5 tachycardia/fibrillation (overlap zone); TS 5
tachy sense.
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AT episode treated by ATP, the reliability of marker
annotations was evaluated using the periods with simulta-
neous AEG storage. The type of AT immediately before
ATP was classified (see earlier text). Primary termination of
AT was defined as immediate termination of the arrhythmia
after ATP. Secondary AT termination was defined, as
suggested in previous studies (10), as arrhythmia termina-
tion within 30 s after ATP. In addition, the atrial cycle
length had to be changed after ATP by $20 ms.
Statistical analysis. This was a prospective observational
study with the primary end points of 1) the incidence of
highly organized AEGs in patients with a history of AT,
including AF; and 2) ATP success rate in relation to AT
organization. Secondary end points were 1) the incidence of
organized AT (type I) in patients with a history of AF only;
2) transition from organized to less organized AT, and vice
versa, during the first minute of the AT episode; and 3) the
potential influence of various clinical factors (e.g., position
of the atrial bipolar lead, gender, age, pacing indication,
presence of coronary artery disease, valvular disease, hyper-
tension, left ventricular ejection fraction, left atrial diameter,
class I or III antiarrhythmic drug treatment) on the AT
type. All data were analyzed using the Statistical Package for
Social Sciences (SPSS, version 8.0), and the statistical
software packages SAS 11 and S-plus 12 (SAS, Cary, North
Carolina). The Student t test or Fisher exact test for
categorical data was used, where appropriate. The Gener-
alized Estimating Equation (GEE [11]) was used to com-
pensate for the different number of episodes from each
patient and to calculate an adjusted percentage of AT type
occurrence with 95% confidence intervals (CIs). Stepwise
logistic regression with the occurrence of type I AT and
ATP success as the dependent variable was performed to
assess the independent contributions of the aforementioned
clinical variables. A p value ,0.05 was considered statisti-
cally significant.
RESULTS
Study group. Forty patients (19 women and 21 men, age
68 6 9 years) with a class I indication for permanent pacing
(26 with sick sinus syndrome, 10 with atrioventricular [AV]
block, 3 with planned AV node ablation, 1 with hypersen-
sitive carotid sinus) and electrocardiographically docu-
mented AT were enrolled in this study. A history of AT
consisted of AF alone in 28 patients (paroxysmal in 26,
persistent in 2), atrial flutter in combination with AF in 3,
atrial flutter alone in 7 and ectopic atrial tachycardia in 2.
Before pacemaker implantation, 3 6 1 (range 1 to 7)
antiarrhythmic drugs had been used for treatment of AT.
Antiarrhythmic drug therapy at enrollment consisted of
amiodarone (n 5 5), sotalol (n 5 5), flecainide (n 5 1),
beta-blocker (n 5 11), calcium antagonist (n 5 4) and
digoxin (n 5 4) and was kept constant during follow-up.
Underlying cardiac disease was present in 32 (80%) of 40
patients: coronary artery disease in 14, hypertension in 20,
valvular disease in 9 and cardiomyopathy in 3. Mean left
ventricular ejection fraction was 0.55 (,0.40 in 7 patients).
Figure 2. Episodes of atrial tachyarrhythmia (AT) (solid bar 5 type I; shaded bar 5 type II; open bar 5 type III) at onset and confirmation of AT
persistence 1 min later on the atrial electrogram (AEGM).
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Mean left atrial diameter was 45 mm ($45 mm in 22
patients). Pacemaker implantation was successfully com-
pleted in all 40 patients, with the atrial lead positioned at
the right atrial free wall in 25 patients (lateral in 15, anterior
in 10) and in the right atrial appendage in 15 patients.
Type of AT. Episodes of AT were stored during the first
study phase in 21 patients. Of these, one patient was
excluded because of insufficient signal quality during AF,
resulting in false detection of AF termination and new-
onset AF. Another patient was excluded because of inap-
propriate AT detection caused by atrial runs of three to five
beats, alternating with two to three sinus beats. Thus,
analysis of AT type during study phase 1 is based on 432
AT episodes in 19 patients. For these 432 AT episodes, 804
AEGs were stored: 392 at AT onset and 412 at AT
confirmation 1 min later. Twenty AEGs showed two AT
types. Thus, a total of 824 AT types were classified (Fig. 2).
Type I was found in 351 (43%), type II in 392 (47%) and
type III in 81 AEGs (10%). The distribution of AT type
among individual patients is shown in Figure 3. Using the
GEE method, the adjusted prevalence of type I AT was
47.5% (95% CI 37.5% to 57.7%), 42.1% (95% CI 29.6% to
55.7%) for type II AT and 9.6% (95% CI 4.9% to 18.1%) for
type III AT.
Type of AT at onset and confirmation. In 279 episodes
recorded during study phase 1, AEG analysis confirmed
correct AT detection at both AT onset and AT confirma-
tion 1 min later (Fig. 3). Of these, 97 AT episodes (35%)
started as type I. At confirmation, 72 (74%) of 97 episodes
remained as type I, whereas 25 (26%) of 97 had degenerated
into type II or III. Of the 182 (65%) of 279 episodes that
started as type II or III, 51 (28%) became organized
secondarily into type I AT within 1 min and 131 (72%)
remained unchanged. Thus, 203 (73%) of 279 AT episodes
exhibited the same degree of organization 1 min after onset,
whereas 76 (27%) of 297 AT episodes changed during this
period.
Type of AT and success of ATP. During the study phase
2, ATP was activated in all patients, and 395 treated AT
episodes were retrieved from the devices. The majority of
episodes were treated immediately after 1 min of AT
persistence; 78% of episodes were treated within 10 min
after AT onset. Of these 395 episodes, 34 were excluded
because of high-degree atrial undersensing or frequent
ventricular far-field oversensing. Of the remaining 361
treated AT episodes (Fig. 4), 217 (60%) were type I and 86
(24%) were type II. Fifty-eight treated AT episodes (16%)
showed type III organization. These were eventually treated
on the basis of relatively regular (e.g., 2:1) undersensing of
AF potentials. Atrial ATP terminated 135 of 217 type I AT
episodes (62%, primary termination in 19%, secondary
termination in 43%) (Fig. 5). Type II AT was successfully
terminated in 29 (34%) of 86 episodes: 1 episode with
primary termination and 28 episodes with secondary termi-
nation. Type III AT episodes could not be terminated by
ATP.
Organized AT in patients with a history of AF. From the
28 patients with surface electrocardiographic documenta-
tion of AF only, 14 had 471 AT episodes stored by the
device (patients 6 to 19 in Fig. 6). Ten patients showed both
type I and type II or III on AEG, whereas in four patients,
all stored AEGs showed type I AT organization. Of these
471 AT episodes, 157 (33%) consisted of type I, 275 (58%)
type II and 39 (8%) type III. Of 12 patients with docu-
mented AF together with atrial flutter (n 5 3) or AT other
than AF (n 5 9), five (2 with exclusively atrial flutter and 3
with atrial flutter and AF) had 332 AT episodes stored by
Figure 3. Number of type I (highly organized) or type II/III (less
organized) atrial tachyarrhythmia (AT) episodes on the atrial electrogram
at onset (left) and after 1 min of AT (right).
Figure 4. Antitachycardia pacing success rates in types I, II and III of atrial tachyarrhythmia (AT) episodes.
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the device. Of these, 192 (58%) showed type I, 101 (30%)
type II and 39 (11%) type III characteristics.
Influence of clinical factors on AT type and ATP
success. On univariate analysis, antiarrhythmic treatment
(class IC and III drugs) was associated with a higher
percentage of type I AT episodes (54% vs. 28%, p , 0.01)
and a lower percentage of type II or III AT episodes (39%
vs. 52%, p , 0.01 and 7% vs. 20%, p , 0.01, respectively).
However, all patients receiving antiarrhythmic drug therapy
exhibited type I and also type II or III AT episodes. On
stepwise logistic regression, no clinical variable, including
antiarrhythmic medication and atrial lead position, was
significantly related to the prevalence of type I versus type II
or III AT. No clinical factors, including age, antiarrhythmic
drug treatment, left atrial diameter and left ventricular
function, showed a significant correlation with ATP suc-
cess.
DISCUSSION
Main study findings. This study demonstrates that in
patients with a history of AF alone or atrial flutter and AF,
a large proportion of spontaneous ATs show highly (43%)
or intermediately (48%) organized AT. Most AT episodes
(73%) remained within the same degree of organization
after 1 min of AT persistence; 26% of type I ATs degen-
erated into less organized forms and 28% of type II or III
ATs became secondarily organized into type I. Atrial ATP
successfully terminated 62% of type I ATs, whereas type II
was only pace-terminable in 34%. Type III could not be
terminated by pacing.
Organization of AT. In this study, evaluation of AT
organization was based on the analysis of bipolar AEGs
recorded at a single site, as a modification of a previously
published classification (9). The automatic cycle length
annotation added important information to the AEG.
Compared with the proposed scheme used in our study,
previous classifications of bipolar electrograms of AT (Table
1) are significantly limited, because they do not consider the
AT cycle length (9,12), they are restricted to cycle length
analysis or signal amplitude variability (13) or they require
particular signal post-processing (14,15). The present study
demonstrates a high prevalence of organized and relatively
slow type I AEGs. In addition, the majority of intermedi-
ately organized ATs (type II) were also regular but faster in
rate; a minority of type II ATs showed polymorphic or
nondiscrete signals or did not display an isoelectric line at
baseline. Only 10% of electrograms were disorganized, with
a loss of discrete signal morphology (type III). Thus,
although human AF has been described as random and
disorganized, the present study reveals evidence that even
patients with AF show AT episodes with a considerable
degree of organization, at least for the first minute after AT
onset. This observation is in line with previous studies
reporting regularity in direction of wavelet propagation
(16,17), as well as temporal and spatial organization during
AF (18,19). Of note, in the present study, all 14 patients
with an exclusive history of AF who developed an AT
episode showed at least one episode of type I on the AEG.
These findings indicate that AF organization may vary
widely within an individual patient, from highly organized
forms suggestive of right atrial flutter to completely disor-
ganized AEG types. Moreover, also during less organized
AT episodes, spells of highly organized arrhythmia amend-
able to ATP may develop. Accordingly, our findings may
Figure 6. Distribution of atrial tachyarrhythmia (AT) types (solid bar 5 type I; open bar 5 type II; shaded bar 5 type III) among individual patients.
In patients 1 and 2, only atrial flutter was previously documented, whereas in patients 3 to 5, atrial fibrillation (AF) and atrial flutter were documented.
The only previously documented AT in patients 6 to 19 was AF.
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serve as a conceptual basis to explain the success or failure of
pace termination of AT.
Termination of AT by atrial ATP. The overall success
rate of atrial ATP was 46% in our study group. Other
studies using implantable devices indicate successful pace
termination in 45% to 95% of AT episodes (20,21). Ac-
cording to device programming (treatment only for regular
AT episodes with a mean cycle length of 220 to 360 ms),
most treated AT episodes showed type I AT, which was
terminated by pacing in 62% of cases. In type II AT
episodes that met the criteria for ATP treatment, ATP
success was significantly lower (34%, p , 0.0001), and type
III AT could not be terminated by ATP. Thus, the
proposed AT classification, based on AEG morphology and
cycle length criteria, correlates well with the success or
failure of atrial ATP. As previously reported (10,22–24),
secondary pace termination of AT occurred in the present
study and was more frequent than primary pace termination.
Transitions between regular and irregular AT. The
present study investigated the time course of spontaneous,
paroxysmal AT episodes during daily life by AEG analysis.
In terms of the degree of organization, 73% of spontaneous
AT episodes were stable, both in episodes starting as
organized type I AT (74%) and in those starting as type II
or III AT (72%). Thus, a 1-min delay before ATP may
avoid unnecessary automatic therapy in short AT episodes,
without increasing the proportion of disorganized AT types.
Similar observations have been made in different clinical
settings. For instance, using temporary leads after cardiac
surgery, transitional AF with a mean duration of 9.3 s before
the onset of typical atrial flutter was found in 78% of
episodes (25). During electrophysiologic study, transitions
from AF to atrial flutter (7), and vice versa (6), have been
found.
Importance of electrode position and antiarrhythmic
drugs. A higher degree of organization of AF along the
trabeculated free right atrial wall, as compared with the
septal region or coronary sinus os, has been reported and
related to “streaming” of excitation along the crista termi-
nalis (6,7). Organization of AT has also been reported to be
dependent on the presence of trabeculated or smooth
myocardium at the site of electrogram recording (26,27).
However, in the present study using bipolar leads implanted
at presumably trabeculated positions, the site of bipolar
electrogram recording was not significantly related to the
type of AT. In the present study, 11 patients were treated
with class I or III antiarrhythmic drugs. Class IC and III
antiarrhythmic drugs may substantially lengthen the AF
wavelength and convert AF into atypical atrial flutter (28).
Accordingly, there was a higher percentage of type I AT
episodes in patients receiving class IC antiarrhythmic or
amiodarone treatment, but all of them also exhibited type II
or III AT episodes.
Study limitations. In this study, all patients with a history
of AT had an indication for permanent pacemaker therapy.
Accordingly, our findings cannot be generalized to all
patients with AT but no need for pacemaker therapy. Some
of the successful secondary terminations by pacing may also
represent a coincidence of ATP delivery and spontaneous
AT cessation. The AEG recordings were obtained from one
endocardial lead located in the right atrium. Thus, no
information on the precise electrophysiologic mechanism
underlying the observed AT could be derived. This is why
we use the term “AT” rather than a more specific diagnosis
of the respective atrial arrhythmia.
Conclusions. A high proportion of patients with a pace-
maker show highly or intermediately organized AT epi-
sodes, even if AF was the only previously documented
arrhythmia. These organized ATs can be successfully ter-
minated by atrial pacing. These findings may serve to derive
new strategies of hybrid therapy of AF which merit pro-
spective evaluation in randomized trials.
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